Batimastat
Batimastat is a drug that was invented by Colin Campion et al. of British Biotech. It is an antimetastatic drug that belongs to the family of drugs called angiogenesis inhibitors. It acts as a matrix metalloproteinase inhibitor by mimicking natural MMPI peptides. Dan Lednicer wrote about this compound in book #6 of his organic drug synthesis series.
Batimastat was the first MMPI that went into clinical trials. First results of a Phase I trial appeared in 1994. The drug reached Phase III but was never marketed; mainly because it couldn't be administered orally, and injection into the peritoneum caused peritonitis.
It is well-known that other methods of administration include transdermal as well as rectal suppositories.
